Health TrialsbyHealthPanel

Mass Balance Study of [14C]DA-302168S in Healthy Chinese Adult Male Participants

ConditionHealthy Adult Subjects
Trial statusNot yet recruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexMale
Age18-55
SponsorChendu DIAO Pharmaceutical Group CO., LTD.

About this trial

In this study, a single dose of \[14C\] radiolabelled DA-302168S will be administered orally. The main purpose of this study is to find out how much of DA-302168S and its metabolites pass from blood into urine and feces, and characterize the metabolic profile and routes of excretion of oral \[14C\] DA-302168S.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

None

Disqualifiers

History or family history of medullary thyroid carcinoma, thyroid C-cell hyperplasia, or MEN2; or serum calcitonin ≥50 ng/L at screening.

Trial design

Design model

Single group

Treatments tested in this trial

  • [14C] DA-302168S

    Drug

    Administered orally

Treatment groups

10 Participants
are divided into 1 treatment group
Group A: [14C] DA-302168SExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Total recovery of HDM1002 radioactivity in urine and feces, following oral administration of [14C] DA-302168S

Time frame
Predose up to Day 8 after administration of [14C]DA-302168S
2

Identification of Major Metabolites in Human Plasma, Urine, and Feces

Time frame
Predose up to Day 8 after administration of [14C]DA-302168S

Secondary outcomes

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Chendu DIAO Pharmaceutical Group CO., LTD.

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: